What are the O‑shot (peri‑urethral platelet‑rich plasma injection) and G‑spot shot (platelet‑rich plasma injection into the anterior vaginal wall) and how are they performed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

O-Shot and G-Spot Shot with PRP: Procedures and Evidence

The O-shot and G-spot shot are platelet-rich plasma (PRP) injection procedures targeting the periurethral area and anterior vaginal wall respectively, but they lack standardized protocols and remain investigational with uncertain clinical utility according to international hematology guidelines 1.

What These Procedures Are

The O-shot involves injecting PRP into the periurethral tissues and clitoral region, while the G-spot shot targets the anterior vaginal wall (the anatomical location of the purported G-spot). Both aim to enhance sexual function, improve orgasmic response, and potentially address urinary incontinence through tissue regeneration.

Procedure Technique

Based on available evidence, the typical protocol involves:

Blood Collection and Processing:

  • Draw 10-60 mL of autologous blood using citrate or ACD anticoagulation (NOT EDTA, which causes platelet activation) 1
  • Centrifuge using variable protocols—commonly 170-200g for 10 minutes, though this varies widely 1
  • Extract the platelet-rich layer, yielding 3-8 mL of PRP
  • Some protocols activate PRP with calcium chloride before injection; others rely on tissue contact for activation 1

Injection Technique:

  • O-shot: Inject 2-4 mL of PRP submucosally into the periurethral area at the anterior vaginal wall mid-urethra level, typically at 4-8 injection sites 2
  • G-spot shot: Inject 2-4 mL into the distal anterior vaginal wall (lower one-third) 3
  • Multiple sessions are common—typically 3-4 treatments spaced 1 month apart 2, 3
  • Local anesthetic cream is usually applied 20-30 minutes before injection

Critical Evidence Gaps and Concerns

The International Society on Thrombosis and Haemostasis (ISTH) 2018 guidelines explicitly state it is "uncertain whether PRP preparations are clinically useful in tissue regenerative techniques" 1. This is the highest-quality guidance available and directly addresses PRP use in regenerative medicine.

Key problems identified:

  • PRP preparations are poorly standardized with complete expert agreement (median score 8.5/9) 1
  • Content, purity, and biological properties vary widely and impact clinical efficacy 1
  • Most studies fail to fully define PRP characteristics (complete agreement, score 9/9) 1

Available Clinical Evidence

Despite guideline uncertainty, recent studies show potential benefits:

For Sexual Dysfunction:

  • A 2019 Turkish study of 52 women showed improved Female Sexual Function Index scores after 4 PRP sessions to the anterior vaginal wall, with orgasm scores increasing from 2.11 to 4.48 (p<0.001) 3
  • A 2026 retrospective study combining fat grafting with PRP showed FSFI improvements of 9.0±2.3 points with 92.1% patient satisfaction 4

For Stress Urinary Incontinence:

  • A 2024 study of 34 women receiving injectable platelet-rich fibrin (i-PRF) to the mid-urethra showed significant improvement in incontinence questionnaires at 6 months (p<0.001) 2

Safety Profile: The 2026 systematic review of 480 patients found PRP injections were associated with "few and mild adverse events" 5. The ISTH guidelines rate autologous PRP as "clinically safe" (score 7.5/8) 1.

Critical Caveats

  1. No standardized protocol exists: Preparation methods, platelet concentrations, injection volumes, number of sessions, and anatomical targets vary dramatically across studies 5

  2. Small sample sizes: Most studies involve fewer than 100 patients with short follow-up periods 5

  3. Lack of placebo-controlled trials: The ISTH emphasizes that proper trials require randomized placebo-controlled designs with validated endpoints 1, which are largely absent in this field

  4. Regulatory status: PRP is classified as a blood product, requiring compliance with blood safety standards, proper labeling, and documentation 6

  5. Variable efficacy: The biological activity depends entirely on preparation method, platelet concentration, and presence/absence of leukocytes—factors rarely reported consistently 1

Practical Recommendations

If proceeding with these procedures:

  • Use citrate or ACD anticoagulation (never EDTA) 1
  • Document baseline platelet counts and final PRP platelet concentration 1
  • Follow sterile technique with proper infection prevention protocols 6
  • Obtain informed consent emphasizing the investigational nature and lack of standardization
  • Consider 3-4 treatment sessions spaced monthly based on existing protocols 2, 3
  • Use validated outcome measures (FSFI, ICIQ-SF, UDI-6) to assess response 2, 3

The most honest clinical approach is to inform patients that while preliminary evidence suggests potential benefits for sexual dysfunction and stress incontinence, these procedures remain investigational with highly variable protocols and uncertain long-term efficacy 1, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.